Key Market Indicators
The Slovak Blood and Blood Forming Organs Medicine market is set to reach $314.8 million by 2026. This represents an average growth rate of 2.6% since 2021, when sales of the medicine reached $267 million. Since 2000, the market has jumped 6% year on year. Slovakia was ranked 19th in 2021, with Finland ahead of it at $267 million in sales. Germany, Italy and South Korea placed second, third and fourth, respectively. The prevalence of anemia in Slovakia is also on the rise. By 2026, hospital discharges due to anemia are expected to reach 9,010, a 1.4% increase from 8,260 in 2021. Since 2005, demand for anemia treatment has grown 2% year on year. Slovakia was the 18th highest in 2021, with Sweden overtaking it at 8,260 hospital discharges. Germany, the United Kingdom and Poland placed second, third and fourth, respectively.
